Published in Circulation on November 04, 1997
Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA (2017) 2.03
Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart (2002) 1.66
Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.41
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart (2004) 0.98
Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc (2014) 0.91
Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr (2013) 0.89
Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J (2010) 0.81
Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ (2012) 0.80
Identification of high risk patients with hypertrophic cardiomyopathy in a northern Greek population. Cardiovasc Ultrasound (2009) 0.80
Abnormal heart rate regulation in murine hearts with familial hypertrophic cardiomyopathy-related cardiac troponin T mutations. Am J Physiol Heart Circ Physiol (2010) 0.80
Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations. Heart Rhythm (2009) 0.78
Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol (2011) 0.78
Effects of lifestyle changes and high-dose β-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy. Cardiol Young (2014) 0.78
Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr Cardiol (2013) 0.76
Orthostatic blood pressure test for risk stratification in patients with hypertrophic cardiomyopathy. PLoS One (2015) 0.75
Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy. Am Heart J (2016) 0.75
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Is the Extent of Septal Hypertrophy Important? PLoS One (2016) 0.75
Working capacity of women doctors. Br Med J (1966) 5.08
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet (2008) 3.87
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India (2007) 3.52
Role of auxilin in uncoating clathrin-coated vesicles. Nature (1995) 3.42
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Prevalence of anaemia in pregnant & lactating women in India. Indian J Med Res (2006) 3.04
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev (2007) 2.78
Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet (1991) 2.77
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart (2008) 2.45
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet (1999) 2.27
Diastolic ventricular interaction in chronic heart failure. Lancet (1997) 2.27
Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 2.26
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart (2004) 2.22
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Measuring brain natriuretic peptide. Lancet (1996) 2.03
Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol (1998) 2.03
Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart (2007) 1.97
Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J (1981) 1.91
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol (1990) 1.91
High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation (2009) 1.83
Human gene for physical performance. Nature (1998) 1.78
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation (1999) 1.76
A conserved clathrin assembly motif essential for synaptic vesicle endocytosis. J Neurosci (2000) 1.75
Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol (2001) 1.74
Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation (1990) 1.73
M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol (1980) 1.72
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Corticosteroids in acute bacterial meningitis. Cochrane Database Syst Rev (2003) 1.68
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart (2000) 1.66
Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol (1992) 1.66
Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation (2001) 1.64
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.60
Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology (2008) 1.57
Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 1.57
Diagnostic criteria for tuberculous meningitis and their validation. Tuber Lung Dis (1994) 1.54
Disappearing CT lesions in epilepsy: is tuberculosis or cysticercosis the cause? J Neurol Neurosurg Psychiatry (1989) 1.52
Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy. Heart (2009) 1.49
Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation (1997) 1.48
Genes and disease expression in hypertrophic cardiomyopathy. Lancet (1998) 1.48
Effect of preoperative supplementation with alpha-tocopherol and ascorbic acid on myocardial injury in patients undergoing cardiac operations. J Thorac Cardiovasc Surg (1997) 1.47
Diastolic ventricular interaction: a possible mechanism for abnormal vascular responses during volume unloading in heart failure. Circulation (1997) 1.46
Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J (1981) 1.46
Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol (1990) 1.45
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation (1999) 1.44
Ventricular tachycardia of left bundle branch block configuration in patients with isolated right ventricular dilatation. Clinical and electrophysiological features. Br Heart J (1984) 1.42
Heart failure is not a diagnosis. Int J Clin Pract (2008) 1.41
Reflex responses of venous capacitance vessels in patients with hypertrophic cardiomyopathy. Clin Sci (Lond) (1998) 1.41
Fragmentation of pulmonary embolus. Lancet (1992) 1.41
Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J (1988) 1.41
Side effects and possible contraindications of amiodarone use. Am Heart J (1983) 1.40
Human chagasic disease is not associated with an antiheart humoral response. Am J Cardiol (1997) 1.40
Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J (1996) 1.39
Difficulty with a flanged tracheostomy tube. Anaesthesia (2005) 1.39
Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation (1992) 1.38
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
Radioactivity in organs of patients receiving radioisotopes: a retraction. N Engl J Med (1977) 1.38
Diagnostic dilemma in flaccid paralysis following anti-rabies vaccine. Neurol India (2004) 1.37
Familial dilated cardiomyopathy in the United Kingdom. Br Heart J (1995) 1.37
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J (1999) 1.36
Amiodarone therapy during pregnancy. Am J Cardiol (1983) 1.35
Regulation of AP-3 function by inositides. Identification of phosphatidylinositol 3,4,5-trisphosphate as a potent ligand. J Biol Chem (1997) 1.33
Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol (1997) 1.32
Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation (1998) 1.31
Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol (1980) 1.30
Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child (1984) 1.29